Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syndax Pharmaceuticals

13.00
+0.08000.62%
Pre-market: 12.11-0.8900-6.85%04:13 EDT
Volume:1.34M
Turnover:17.50M
Market Cap:1.12B
PE:-3.49
High:13.59
Open:13.35
Low:12.81
Close:12.92
Loading ...

Syndax Pharmaceuticals Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

Syndax announces additional positive data from AUGMENT-101 trial of Revuforj

TIPRANKS
·
09 Dec 2024

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), UnitedHealth (UNH) and Disc Medicine (IRON)

TIPRANKS
·
09 Dec 2024

Syndax Pharmaceuticals Inc -Plans to Initiate Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024

THOMSON REUTERS
·
09 Dec 2024

Syndax Announces Additional Positive Data for Revuforj® (Revumenib) From Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial

THOMSON REUTERS
·
09 Dec 2024

Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

THOMSON REUTERS
·
09 Dec 2024

Positive Outlook for Syndax Pharmaceuticals Amid Efficacy and Safety Considerations

TIPRANKS
·
09 Dec 2024

Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias From Multiple Trials, Including the Save Combination and Augment-101 Trials, at 66TH Ash Annual Meeting

THOMSON REUTERS
·
08 Dec 2024

Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey
·
05 Dec 2024

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

seekingalpha
·
26 Nov 2024

Analysts supportive of Kura/Kirin deal despite major selloff in shares

seekingalpha
·
22 Nov 2024

Syndax Pharmaceuticals Inc : JP Morgan Raises Target Price to $38 From $33

THOMSON REUTERS
·
21 Nov 2024

Syndax Pharmaceuticals (SNDX) Gets a Buy from Barclays

TIPRANKS
·
19 Nov 2024

Syndax Pharmaceuticals’ Promising Outlook: Revumenib Approval and Market Potential Justify Buy Rating

TIPRANKS
·
19 Nov 2024

Syndax Pharmaceuticals Shares Rise 4.2% After FDA Approves Co's Blood Cancer Drug

THOMSON REUTERS
·
18 Nov 2024

Syndax Pharmaceuticals (SNDX) Gets a Buy from TD Cowen

TIPRANKS
·
18 Nov 2024

Syndax price target raised to $51 from $49 at H.C. Wainwright

TIPRANKS
·
18 Nov 2024

Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects

TIPRANKS
·
18 Nov 2024

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals

Reuters
·
18 Nov 2024

Syndax Pharmaceuticals Inc : Jefferies Raises Target Price to $43 From $37

THOMSON REUTERS
·
18 Nov 2024